Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

Pigment Cell Melanoma Res. 2015 Sep;28(5):607-10. doi: 10.1111/pcmr.12388. Epub 2015 Jul 3.

Authors

Alexander M Menzies^{1

2}, Iwei Yeh³, Thomas Botton³, Boris C Bastian³, Richard A Scolyer^{1

2

4}, Georgina V Long^{1

2}

Affiliations

¹ Melanoma Institute Australia, Sydney, NSW, Australia.
² The University of Sydney, Sydney, NSW, Australia.
³ Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
⁴ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / diagnosis
Brain Neoplasms / pathology
Brain Neoplasms / secondary
Carrier Proteins / metabolism
DNA Mutational Analysis
Disease Progression
Female
Humans
Intracellular Signaling Peptides and Proteins
MAP Kinase Kinase Kinases / antagonists & inhibitors*
Magnetic Resonance Imaging
Male
Melanoma / drug therapy*
Melanoma / genetics
Membrane Proteins / metabolism
Middle Aged
Neoplasm Metastasis
Oncogene Proteins, Fusion / metabolism
Proto-Oncogene Proteins B-raf / metabolism*
Pyridones / therapeutic use*
Pyrimidinones / therapeutic use*
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
BRAF-KIAA1549 fusion protein, human
Carrier Proteins
Intracellular Signaling Peptides and Proteins
Membrane Proteins
Oncogene Proteins, Fusion
PPFIBP2 protein, human
Pyridones
Pyrimidinones
trametinib
pembrolizumab
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase Kinases

Grants and funding

P01 CA025874/CA/NCI NIH HHS/United States